Exscientia has announced that DSP-0038, a novel small molecule inhibitor developed in collaboration with Sumitomo Dainippon Pharma, is shortly to enter Phase 1 clinical trials for treatment of Alzheimer's disease (AD) psychosis. DSP-0038 is a small molecule drug designed to block a serotonin receptor called 5-HT2A, whilst activating a similar serotonin receptor called 5-HT1A. DSP-0038 was designed using Exscientia's AI technology, which is able to quickly model drug interactions by processing and analysing large quantities of data. DSP-0038 was chosen to enter a Phase 1 clinical trial based on its potency and selectivity, targeting the desired receptors whilst avoiding similar receptors and unwanted targets. It is hoped that by selectively targeting these two serotonin receptors, DSP-0038 will work as an effective antipsychotic in AD, also improving symptoms such as aggression, anxiety and agitation. The clinical trial will take place in the US and will be led by Sumitomo Dainippon Pharma.